Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board
1. Decoy Therapeutics merges with Salarius Pharmaceuticals to form a new company. 2. Dr. Robert S. Langer will join Decoy's Scientific Advisory Board post-merger. 3. Langer's expertise could enhance drug development of antiviral and cancer therapies. 4. Salarius's lead candidate, seclidemstat, is in clinical trials for hematologic cancers. 5. The combined company aims to leverage innovative peptide-conjugate therapeutics.